Eleven Biotherapeutics

Press Releases
 
Press Releases
Date Title and Summary View
April 29, 2016 Preclinical Data on EBI-031 in Diabetic Macular Edema and Clinical Data on Isunakinra (EBI-005) in Dry Eye Disease and Allergic Conjunctivitis to be Presented CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and...
March 24, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a preclinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2015 and pr...
January 26, 2016 Cambridge, MA and Copenhagen, Denmark - January 26, 2016 - Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) and Albumedix (DK A/S) today announced that Eleven and Albumedix have entered into an agreement that will see Albumedix acquire Eleven's proprietary Supermin® albumin variant assets. Albumedix is a world leader in albumin engineer...
January 15, 2016 -Isunakinra Misses Primary Endpoint of Ocular Itching- -Company Plans to Advance Development of EBI-031 for Diabetic Macular Edema and Uveitis with an IND Submission Planned for the First Half of 2016- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. ...
November 4, 2015 Management to host conference call today at 8:30 a.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial ...
October 27, 2015 Conference call scheduled for November 4, 2015 at 8:30 a.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced it will ...
October 15, 2015 -Eleven Granted Isunakinra as the International Nonproprietary Name for EBI-005- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, ...
September 1, 2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced the promotions of Gary Sternberg, MD, MBA, to Chief Business Officer and John McCabe, CPA, to...
August 31, 2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, PhD, President and Chief Executive Officer, will present a company ...
August 13, 2015 Management to host conference call today at 8:30 a.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial ...
FirstPrevious
3
... NextLast
Add to Briefcase = add release to Briefcase
NASDAQ: EBIO
Price:
1.33
Change:
- 0.03
Day High:
1.39
Day Low:
1.32
Volume:
413,710
3:28 PM ET on May 24, 2017
Delayed at least 20 minutes.